Revvity (NYSE:RVTY) Upgraded at UBS Group

UBS Group upgraded shares of Revvity (NYSE:RVTY - Free Report) from a neutral rating to a buy rating in a report published on Thursday, MarketBeat.com reports. The firm currently has $115.00 price target on the stock, down from their previous price target of $145.00.

Other research analysts have also issued research reports about the company. JPMorgan Chase & Co. reduced their target price on Revvity from $120.00 to $100.00 and set a "neutral" rating for the company in a report on Tuesday, April 29th. The Goldman Sachs Group decreased their price objective on shares of Revvity from $140.00 to $125.00 and set a "buy" rating on the stock in a research report on Tuesday, April 29th. KeyCorp raised their price target on Revvity from $132.00 to $145.00 and gave the company an "overweight" rating in a research report on Monday, February 3rd. Sanford C. Bernstein lowered shares of Revvity from an "outperform" rating to a "market perform" rating and set a $130.00 target price on the stock. in a report on Friday, January 10th. Finally, Robert W. Baird dropped their price objective on Revvity from $127.00 to $125.00 and set an "outperform" rating for the company in a research note on Tuesday, April 29th. Four investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $125.64.

Revvity Stock Performance

Shares of RVTY stock traded down $2.77 during trading hours on Thursday, hitting $90.06. 279,541 shares of the company were exchanged, compared to its average volume of 927,604. Revvity has a 52-week low of $88.53 and a 52-week high of $129.50. The company has a current ratio of 3.60, a quick ratio of 3.03 and a debt-to-equity ratio of 0.41. The firm has a fifty day simple moving average of $102.35 and a 200 day simple moving average of $111.83. The stock has a market capitalization of $10.82 billion, a price-to-earnings ratio of 40.69, a P/E/G ratio of 3.82 and a beta of 1.02.

Revvity (NYSE:RVTY - Get Free Report) last issued its earnings results on Monday, April 28th. The company reported $1.01 earnings per share for the quarter, topping analysts' consensus estimates of $0.96 by $0.05. The firm had revenue of $664.76 million during the quarter, compared to analyst estimates of $662.30 million. Revvity had a net margin of 9.81% and a return on equity of 7.68%. The company's quarterly revenue was up 2.3% on a year-over-year basis. During the same quarter last year, the business earned $0.98 earnings per share. Research analysts predict that Revvity will post 4.94 earnings per share for the current fiscal year.

Revvity Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 8th. Shareholders of record on Friday, July 18th will be issued a dividend of $0.07 per share. The ex-dividend date of this dividend is Friday, July 18th. This represents a $0.28 dividend on an annualized basis and a yield of 0.31%. Revvity's dividend payout ratio is currently 11.91%.

Institutional Investors Weigh In On Revvity

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Assetmark Inc. increased its holdings in shares of Revvity by 3,700.0% in the fourth quarter. Assetmark Inc. now owns 266 shares of the company's stock worth $30,000 after purchasing an additional 259 shares during the last quarter. Optiver Holding B.V. purchased a new stake in Revvity during the fourth quarter valued at approximately $33,000. Quarry LP lifted its stake in shares of Revvity by 45.7% in the 4th quarter. Quarry LP now owns 303 shares of the company's stock valued at $34,000 after purchasing an additional 95 shares during the last quarter. Millstone Evans Group LLC purchased a new position in shares of Revvity in the 4th quarter worth approximately $38,000. Finally, Vermillion Wealth Management Inc. purchased a new stake in Revvity during the 4th quarter valued at $41,000. Institutional investors own 86.65% of the company's stock.

About Revvity

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.